IMBRUVICA: payments to doctors
Payments that named IMBRUVICA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $12.7M
- Providers
- 18,589
- Transactions
- 136,281
- Average per transaction
- $93
The per-transaction average — $93 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 18,589 providers the average total is $682, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $5,911,858 | 46.6% |
| Johnson & Johnson | $4,611,183 | 36.4% |
| AbbVie | $1,075,516 | 8.5% |
| Janssen Scientific Affairs, LLC | $549,472 | 4.3% |
| Janssen Global Services, LLC | $493,377 | 3.9% |
| Janssen Research & Development, LLC | $32,256 | 0.3% |